Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver symbols : GILD save search
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | News | $9.49 480K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.825 -0.34% 9.7M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $168.21 -0.78% 1.2M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $46.765 -1.94% 950K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $144.52 -1.06% 140K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: -0.35%
H: 2.36%
C: 1.42%
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 27.92%
H: 0.97%
C: 0.88%
liver acquisition sciences therapeutics
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
Published: 2023-11-03 (Crawled : 17:00) - biospace.com/
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: 0.95%
H: 0.72%
C: -0.5%
meeting hepatitis liver world
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
Published: 2023-06-14 (Crawled : 09:00) - biospace.com/
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: -0.52%
H: 0.46%
C: -0.12%
liver disease association research study
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
Published: 2022-11-01 (Crawled : 16:00) - biospace.com/
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: -0.25%
H: 1.65%
C: 1.38%
meeting treatment hepatitis fibrosis liver disease living
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
Published: 2022-06-21 (Crawled : 14:00) - biospace.com/
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: 0.0%
liver disease international
Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients
Published: 2021-11-29 (Crawled : 15:00) - biospace.com/
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
AMZN S | $177.26 -1.27% 20M
|
Retail Trade
|
| O: 1.2%
H: 0.0%
C: 0.0%
liver collaboration
Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®
Published: 2021-11-09 (Crawled : 15:15) - biospace.com/
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
disease liver disease liver
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
Published: 2021-06-25 (Crawled : 13:00) - globenewswire.com
VIR | $8.205 0.92% 240K
|
Health Technology
|
| O: -0.52%
H: 1.36%
C: -7.74%
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: -0.06%
H: 1.28%
C: 1.1%
ALNY | $144.52 -1.06% 140K
|
Health Technology
|
| O: 0.26%
H: 1.5%
C: 0.72%
hepatitis ongoing biotech technology iot liver trial injection infections chronic hepatitis b
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
Published: 2021-06-21 (Crawled : 11:00) - biospace.com/
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: 0.57%
H: 0.86%
C: 0.54%
disease liver disease liver
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
Published: 2020-12-07 (Crawled : 12:00) - globenewswire.com
GILD | $66.99 -0.06% 3.3M
|
Health Technology
|
| O: 0.17%
H: 0.06%
C: -1.35%
MTNB | $0.1806 -0.5% 310K
|
Health Technology
|
| O: 10.09%
H: 4.17%
C: -7.5%
biopharma collaboration disease announces collaboration liver infectious disease antiviral
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.85 51.79% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
MULN | News | $3.805 39.38% 11M
|
Information
RILY | $30.01 38.17% 11M
|
Finance
MTC | $3.04 35.71% 6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.